Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Nivolumab extends survival for NSCLC

2015 ASCO Annual Meeting

29 May - 2 Jun 2015

Published: 29 May 2015

Views: 3067

Rating:

Save

Prof Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Dr Luis Paz-Ares presents at ASCO 2015 data from a randomised phase III study that indicate PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small cell lung cancer (NSCLC).

Read the news article and watch the interview.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Immunotherapy developments and new agents for locally advanced NSCLC and SCLC

Dr Edgardo Santos - Florida Precision Oncology, Florida, USA

Immunotherapy developments and new agents for locally advanced NSCLC and SCLC ( Dr Edgardo Santos - Florida Precision Oncology, Florida, USA )

Predictive and prognostic biomarkers for immunotherapy in lung cancer

Dr Ignacio Gil Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...

Predictive and prognostic biomarkers for immunotherapy in lung cancer ( Dr Ignacio Gil Bazo - Fundación Instituto Valenciano de Oncología (FIVO), Valencia, Spain )

Immunotherapy in NSCLC: Adjuvant and neoadjuvant clinical scenarios

Dr Luis Raez - Memorial Healthcare System, Florida, USA

Immunotherapy in NSCLC: Adjuvant and neoadjuvant clinical scenarios ( Dr Luis Raez - Memorial Healthcare System, Florida, USA )

ASCO 2023: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2023: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Neoadjuvant nivolumab plus chemotherapy continues to provide long-term clinical...

Prof Nicolas Girard - Institut Curie, Paris, France

Neoadjuvant nivolumab plus chemotherapy continues to provide long-term clinical benefit in patients with resectable NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Four chemo cycles given with durvalumab and tremelimumab optimise response and...

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )

More from ecancer